BTB09089
Based on 1 publication(s) in Google Scholar
BTB09089 is a T cell death-associated gene 8 (TDAG8/GPR65) specific agonist. BTB09089 increases TDAG8 expression and regulates the cytokine production of T cells and macrophages.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.39%
- CAS. Nr.: 245728-44-3
- Formel: C14H12Cl2N4OS2
- Molecular Weight:387.31
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) BTB09089
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
Biologische Aktivität
TDAG8/GPR65[1]
BTB09089 (0-18 μM; 30 min) significantly increases cAMP accumulation in hTDAG8 and mTDAG8 transiently expressing HEK293 cells, but not in control HEK 293 cells. BTB09089 does not increase cAMP accumulation in hGPR4 expressing HEK293 cells nor does it increase inositol phosphate accumulation in hOGR1 expressing HEK293 cells[1].
BTB09089 (0-18 μM; 30 min) significantly enhances the cAMP accumulation in a dose-dependent manner at pH 7.0-7.9 but not at pH 6.5[1].
BTB09089 (1-5 μM; 20 h) suppresses IL-2 production in splenocytes from WT mice in a dose-dependent manner but not from TDAG8 KO mice without affecting the cell viability[1].
BTB09089 (1-5 μM; 18 h) suppresses LPS (HY-D1056)-stimulated TNF-α and IL-6 production, and enhances LPS-stimulated IL-10 production in thioglycollate induced peritoneal exude cells (TG-PEC)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male SD rats (270-280 g), middle cerebral artery occlusion (MCAO) model[2]
-
Dosage:5, 10 and 20 μM, 8 μL
-
Administration:Intracerebroventricular injection, six hours prior to MCAO
-
Result:Up-regulated TDAG8 and Bcl-2 expression and down-regulated cleaved caspase-3 expression, while the infarction volume was reduced, and neurological deficits were ameliorated 24 and 72 h after MCAO.
Chemical Information
-
CAS. Nr. 245728-44-3
-
Appearance Solid
-
Molecular Weight 387.31
-
Formel C14H12Cl2N4OS2
-
Color Yellow to orange
-
SMILES
O=C1C2=C(C=NN1C)N(C)N=C(SCC3=CC=C(C=C3Cl)Cl)S2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Stroke
Targeting Neuronal GPR65 With Delayed BTB09089 Treatment Improves Neurorehabilitation Following Ischemic Stroke. [Abstract]2024 Aug;55(8):2151-2162. PMID: 38946544
BTB09089 purchased from MedChemExpress. Usage Cited in: Stroke. 2024 Aug;55(8):2151-2162. [Abstract]
To determine the optimal dose of BTB09089 for motor functional recovery, mice were injected with 0.19, 0.38, or 0.76 mg/kg of BTB09089 every other day from 3 to 21 days after PTI.
BTB09089 purchased from MedChemExpress. Usage Cited in: Stroke. 2024 Aug;55(8):2151-2162. [Abstract]
Behavioral assessment revealed that 0.76 mg/kg of BTB09089 both significantly reduced the number of left forelimb foot faults and the forelimb bias at days 7, 14, and 21 poststroke, while 0.19 or 0.38 mg/kg of BTB09089 had no benefits on motor outcomes. Therefore, 0.76 mg/kg of BTB09089 was chosen for the follow-up experiments. Moreover, the infarct volume in the 0.76 mg/kg of BTB09089 group was smaller than that in the PTI group at day 21 poststroke.
BTB09089 purchased from MedChemExpress. Usage Cited in: Stroke. 2024 Aug;55(8):2151-2162. [Abstract]
To explore the therapeutic time window of BTB09089, 0.76 mg/kg of BTB09089 was applied every other day at days 3-35, 7-35, or 14-35 after PTI.
BTB09089 purchased from MedChemExpress. Usage Cited in: Stroke. 2024 Aug;55(8):2151-2162. [Abstract]
We examined whether the number of neurons, microglial activation, and glial scar formation are mediated by BTB09089. BTB09089 significantly reduced the decrease of neuronal number.
BTB09089 purchased from MedChemExpress. Usage Cited in: Stroke. 2024 Aug;55(8):2151-2162. [Abstract]
BTB09089 markedly reduced the thickness of GFAP-labeled glial scars in WT mice.
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (258.19 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (12.91 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Onozawa Y, et al. Activation of T cell death-associated gene 8 regulates the cytokine production of T cells and macrophages in vitro. Eur J Pharmacol. 2012 May 15;683(1-3):325-31. [Content Brief]
[2]. Ma XD, et al. TDAG8 activation attenuates cerebral ischaemia-reperfusion injury via Akt signalling in rats. Exp Neurol. 2017 Jul;293:115-123. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5819 mL | 12.9096 mL | 25.8191 mL | 64.5478 mL |
| 5 mM | 0.5164 mL | 2.5819 mL | 5.1638 mL | 12.9096 mL | |
| 10 mM | 0.2582 mL | 1.2910 mL | 2.5819 mL | 6.4548 mL | |
| 15 mM | 0.1721 mL | 0.8606 mL | 1.7213 mL | 4.3032 mL | |
| 20 mM | 0.1291 mL | 0.6455 mL | 1.2910 mL | 3.2274 mL | |
| 25 mM | 0.1033 mL | 0.5164 mL | 1.0328 mL | 2.5819 mL | |
| 30 mM | 0.0861 mL | 0.4303 mL | 0.8606 mL | 2.1516 mL | |
| 40 mM | 0.0645 mL | 0.3227 mL | 0.6455 mL | 1.6137 mL | |
| 50 mM | 0.0516 mL | 0.2582 mL | 0.5164 mL | 1.2910 mL | |
| 60 mM | 0.0430 mL | 0.2152 mL | 0.4303 mL | 1.0758 mL | |
| 80 mM | 0.0323 mL | 0.1614 mL | 0.3227 mL | 0.8068 mL | |
| 100 mM | 0.0258 mL | 0.1291 mL | 0.2582 mL | 0.6455 mL |
BTB09089 Related Classifications
HY-149164 Related Classifications
Powered by Bioz